Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor...
Publications
1 shownFrequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 1
- Citations
- 6,054
- Institution
- Merck & Co., Inc., Rahway, NJ, USA (United States)
External Links
Identifiers
- ORCID
- 0000-0001-7241-0760
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.